SHANGHAI – Cellular Biomedicine Group Inc., a stem cell and immunotherapy company headquartered in Shanghai, has acquired Beijing Agreen Biotech Co. Ltd. The deal will bring patents, people and the promise of revenue to its new owner.

SHANGHAI – Cellular Biomedicine Group Inc., a stem cell and immunotherapy company headquartered in Shanghai, has acquired Beijing Agreen Biotech Co. Ltd. The deal will bring patents, people and the promise of revenue to its new owner.

HONG KONG – It's been more than a year since Chinese authorities leveled allegations against Glaxosmithkline plc (GSK) for corrupt activities amounting to almost $500 million in bribes, setting off an industrywide crackdown that has garnered the attention of not only the Chinese, but also the U.S. and UK anti-corruption authorities.

HONG KONG – It's been more than a year since Chinese authorities leveled allegations against Glaxosmithkline plc (GSK) for corrupt activities amounting to almost $500 million in bribes, setting off an industrywide crackdown that has garnered the attention of not only the Chinese, but also the U.S. and UK anti-corruption authorities.

SHANGHAI – Yabao Pharmaceutical Co. Inc. has agreed to co-develop with Le Sun Pharmaceutical Ltd. their leading PLK/PI3K dual inhibitor LS-008. On its hunt to find candidates with global potential, Chinese pharma Yabao will team up with the local biotech to accelerate development for the preclinical oncology candidate.

SHANGHAI – Sotio AS, of Prague, has expanded its China footprint with the opening of a GMP, clean-room lab for the production of active cellular immunotherapy treatments against cancer diseases. This is their second facility, giving them a combined lab space of 1,000 square meters in Beijing. Sotio will produce therapeutic cellular treatments for patients with prostate and lung cancer.

SHANGHAI – For Xueming Qian, CEO and founder of Mabspace Co. Ltd., an antibody discovery engine based in Suzhou, the writing was on the wall. While pharma was de-emphasizing early stage research and putting it into the hands of biotechs in the U.S., the economy in China had hit an inflection point, the momentum was building. China was the place to be.

SHANGHAI – For Xueming Qian, CEO and founder of Mabspace Co. Ltd., an antibody discovery engine based in Suzhou, the writing was on the wall. While pharma was de-emphasizing early stage research and putting it into the hands of biotechs in the U.S., the economy in China had hit an inflection point, the momentum was building. China was the place to be.

SHANGHAI – Merck KGaA, of Darmstadt, Germany, has reiterated its commitment to China, forging ahead with its €80 million (US$107.3 million) manufacturing plant, expected to be Merck's second largest globally and its first such pharmaceutical investment in China.

SHANGHAI – Canbridge Life Sciences Inc., of Beijing, is on its way to bridging the gap that leaves many patients in China waiting anywhere from four years to six years for critical treatments approved in developed markets. With time of the essence, the firm is taking a portfolio approach to its in-licensing strategy, developing both clinical-stage and approved treatments, while mixing new drugs with treatments classified as medical devices.